This is a randomized double blind placebo-controlled clinical trial study designed to evaluate the efficacy of 400 micg of misoprostol prescript sublingual, in comparison with vaginal prescription, on cervical ripening before curative or diagnostic hysteroscopy. 100 patients were randomly assigned to the following treatment regimen . The vaginal group received 400 micg of misoprostol (placed into the posterior vaginal fornix) and at the same time received one tablet of vitamin B6 as placebo. The sublingual group received 400 micg of misoprostol sublingually and at the same time received one tablet of vitamin B6 as placebo. Duration of cervical dilatation time in with 9 hegar could be inserted and the complications of hysteroscopy (cervical tearing, creation of a false track, uterine perforation and bleeding) were interpreted as the outcome. The inclusion criteria: woman who gave consent for operative-diagnostic hysteroscopy, and were of reproductive age(i.e; were premenopausal) and not pregnant at the time of presentation. The exclusion criteria: contraindication to PGs(history of severe asthma, glaucoma, preexisting cardiac disease, hypertension, or renal failure), significant uterovaginal prolapsed precluding the administration of vaginal tablets, or history of cervical surgery or cervical incompetency, women who had sub mucosal fibroma larger than 2 cm (because of partial dilatation of cervix).